We are a World-leading molecular oncology facility with a fully equipped laboratory, integrated process platforms, in-house bioinformatics team, and a huge genetic data base for precise and updated reporting.
The facility is NABL, ISO, CAP and CLIA accredited. National and international cancer research institutes, and patients from all over the world including US, Switzerland, Germany and UK avail our services.
With the help of latest technology and several years of extensive research, we offer highly effective treatment solutions to cancer patients for whom, multiple lines of treatment have failed.
Our state-of-the-art cancer research centre is spread over 40,000 sq.ft. with a formidable team of cancer researchers, doctors, scientists and other technologists educated and trained at top universities and institutes around the world. Our entire team is always at the disposal of clinicians and cancer patients to bring cutting-edge treatment options in the most challenging cases.
The facility is NABL, ISO, CAP and CLIA accredited. National and international cancer research institutes, and patients from all over the world including US, Switzerland, Germany and UK avail our services.
With the help of latest technology and several years of extensive research, we offer highly effective treatment solutions to cancer patients for whom, multiple lines of treatment have failed.
Our state-of-the-art cancer research centre is spread over 40,000 sq.ft. with a formidable team of cancer researchers, doctors, scientists and other technologists educated and trained at top universities and institutes around the world. Our entire team is always at the disposal of clinicians and cancer patients to bring cutting-edge treatment options in the most challenging cases.
Location: India, Maharashtra, Nashik
Employees: 51-200
Founded date: 1992
Investors 1
| Date | Name | Website |
| 17.05.2025 | Alkemi Ven... | alkemivp.c... |
Mentions in press and media 12
| Date | Title | Description |
| 05.03.2025 | Datar Cancer Genetics & Theranomics Unveil AI-Powered Platform to Personalise Cancer Treatment in Mexico | Exacta AI signifies a paradigm shift in the approach to treatment decision making for complex cancer cases, offering an unprecedented level of precision in generating treatment options.” — Dr Vineet DattaLONDON, UNITED KINGDOM, March 5, 202... |
| 14.10.2024 | Datar Cancer Genetics Showcases New Multi-Omics Tumor Profiling Data at MAP Oncology Congress 2024 | The multi-analyte, multi-platform Exacta™ solution offers a unique combination of detailed molecular analysis, comprehensive gene expression based pathway review, and cytotoxic therapy guidance.” — Dr Darshana PatilGUILDFORD, UNITED KINGDOM... |
| 31.05.2024 | Datar Cancer Genetics Publishes Real-World Data Highlighting the Benefits of Multi-Omics Tumor Profiling at ASCO 2024 | Datar Cancer Genetics GUILDFORD, SURREY, UNITED KINGDOM, May 31, 2024 /EINPresswire.com/ -- Datar Cancer Genetics (DCG) today announced the publication of data related to the clinical utility and benefits of multi-omics tumor profiling at t... |
| 28.05.2024 | Datar Cancer Genetics To Share Key Scientific Findings at the 2024 American Society of Clinical Oncology Annual Meeting | GUILDFORD, SURREY, UNITED KINGDOM, May 28, 2024 /EINPresswire.com/ -- Datar Cancer Genetics (DCG) today announced it will release ten scientific data sets across its diverse oncology portfolio at the 2024 American Society of Clinical Oncolo... |
| 02.01.2023 | US FDA Grants Breakthrough Designation for Blood Test to Help Diagnose Inaccessible Brain Tumors | The liquid biopsy has been developed by Datar Cancer Genetics to help diagnose brain tumors where a conventional biopsy is not possible. A prospective, blinded study by a research team at the Imperial College, London showed very high accura... |
| 17.10.2022 | Datar Cancer Genetics Partners With AVMLabs To Offer Trucheck Cancer Screening Solution Across Bahrain | Datar Cancer Genetics state of art lab facility Trucheck is a CE-accredited, blood based solution that offers early cancer detection, including for those cancers which currently do not have a standard screening process for detection” — Dr V... |
| 13.06.2022 | DATAR CANCER GENETICS PARTNERS WITH THE CANCER SCREENING TRUST TO OFFER BLOOD-BASED TEST FOR EARLY CANCER DETECTION | Datar Cancer Genetics UK lab facility Trucheck is a comprehensive and highly accurate cancer screening solution, that can enable early detection of multiple cancers in asymptomatic individuals” — Dr Vineet DattaLONDON, UNITED KINGDOM, June ... |
| 12.04.2022 | DATAR CANCER GENETICS PARTNERS WITH ARTEMIS DNA TO OFFER BLOOD-BASED TEST FOR EARLY CANCER DETECTION IN VIETNAM | Datar Cancer Genetics lab facility Our commitment is to deliver best-in-class and unparalleled range of blood-based diagnostics and work with Artemis DNA towards ensuring freedom from the fear of cancer for the people of Vietnam” — Rajan Da... |
| 11.04.2022 | DATAR CANCER GENETICS ENTERS INTO PARTNERSHIP WITH THE LONDON CLINIC TO OFFER ENHANCED CANCER TESTING SERVICES | This collaboration will provide advanced cancer genomics to the patient community, and we will work closely with The London Clinic oncology team to support better informed clinical decision making” — Dr Vineet DattaLONDON, UNITED KINGDOM, A... |
| 20.11.2021 | US FDA Grants Breakthrough Designation for Early-Stage Breast Cancer Detection Blood Test Developed by Datar Cancer Genetics | LONDON, Nov. 20, 2021 /PRNewswire/ -- Datar Cancer Genetics, a leading cancer research company focussed on early detection of cancers today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designatio... |
Show more